1
|
Hagstrom R, Nossek E, Rutledge CW, Ponchione E, Suryadevara C, Kremer C, Alcon A, Sharashidze V, Shapiro M, Raz E, Nelson PK, Staffenberg DA, Riina HA. Transpalpebral/Blepharoplasty Incision and Supraorbital Craniotomy for the Treatment of Ethmoidal Dural Arteriovenous Fistulas: A Case Series. Oper Neurosurg (Hagerstown) 2024:01787389-990000000-01066. [PMID: 38376155 DOI: 10.1227/ons.0000000000001103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Accepted: 01/03/2024] [Indexed: 02/21/2024] Open
Abstract
BACKGROUND AND OBJECTIVES Inherent complex angioarchitecture associated with ethmoidal dural arteriovenous fistulas (dAVFs) can make endovascular treatment methods challenging. Many surgical approaches are accompanied by unfavorable cosmetic results such as facial scarring. Blepharoplasty incision of the eyelid offers a minimal, well-hidden scar compared with other incision sites while offering the surgeon optimal visualization of pathogenic structures. This case series aims to report an initial assessment of the safety and efficacy of supraorbital craniotomy by blepharoplasty transpalpebral (eyelid) incision for surgical disconnection of ethmoidal dAVFs. METHODS Retrospective chart review was conducted for all patients who underwent blepharoplasty incision and craniotomy for disconnection of ethmoidal dAVFs at our institution between October 2011 and February 2023. Patient charts and follow-up imaging were reviewed to report clinical and angiographic outcomes as well as periprocedural and follow-up complications. RESULTS Complete obliteration and disconnection of ethmoidal dAVF was achieved in all 6 (100%) patients as confirmed by intraoperative angiogram with no resulting morbidity or mortality. Periprocedural complications included one case of transient nasal cerebrospinal fluid leak that was self-limiting and resolved before discharge without intervention. CONCLUSION Surgical treatment for ethmoidal dAVFs, specifically by transpalpebral incision and supraorbital craniotomy, is a safe and effective treatment option and affords the surgeon greater access to the floor of the anterior fossa when necessary. In addition, blepharoplasty incision addressed patient concerns for facial scarring compared with other incision sites by creating a more well-hidden, minimal scar in the natural folds of the eyelid for patients with an eyelid crease.
Collapse
Affiliation(s)
- Rory Hagstrom
- Department of Neurosurgery, NYU Langone Health, New York, New York, USA
| | - Erez Nossek
- Department of Neurosurgery, NYU Langone Health, New York, New York, USA
| | - Caleb W Rutledge
- Department of Neurosurgery, NYU Langone Health, New York, New York, USA
| | | | | | - Caroline Kremer
- Department of Neurosurgery, NYU Langone Health, New York, New York, USA
| | - Andre Alcon
- Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, New York, USA
| | - Vera Sharashidze
- Department of Neurology, NYU Langone Health, New York, New York, USA
| | - Maksim Shapiro
- Department of Radiology, NYU Langone Health, New York, New York, USA
| | - Eytan Raz
- Department of Radiology, NYU Langone Health, New York, New York, USA
| | - Peter K Nelson
- Department of Radiology, NYU Langone Health, New York, New York, USA
| | - David A Staffenberg
- Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, New York, USA
| | - Howard A Riina
- Department of Neurosurgery, NYU Langone Health, New York, New York, USA
| |
Collapse
|
2
|
Hayek R, Mehuron T, Geevarghese A, Bilici N, Koen N, Warren F, Suryadevara C, Nossek E, Buciuc R, Lewis A. Bilateral subperiosteal orbital hematomas following cerebral aneurysm embolization: An atypical presentation of acute vision loss. J Clin Neurosci 2024; 119:220-221. [PMID: 38154176 DOI: 10.1016/j.jocn.2023.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Accepted: 12/07/2023] [Indexed: 12/30/2023]
Affiliation(s)
- Reya Hayek
- New York University Langone Medical Center, United States.
| | - Thomas Mehuron
- New York University Langone Medical Center, United States
| | | | - Nadir Bilici
- New York University Langone Medical Center, United States
| | - Nicholas Koen
- New York University Langone Medical Center, United States
| | - Floyd Warren
- New York University Langone Medical Center, United States
| | | | - Erez Nossek
- New York University Langone Medical Center, United States
| | | | - Ariane Lewis
- New York University Langone Medical Center, United States
| |
Collapse
|
3
|
Shen S, Cook S, Suryadevara C, Hotchkiss K, Snyder D, Sanchez-Perez L, Sampson J. EXTH-53. IL-12 ARMORED CAR T CELL THERAPY FOR HETEROGENEOUS GLIOBLASTOMA. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac209.851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
INTRODUCTION
Chimeric antigen receptor (CAR) T cells specific for the glioblastoma (GBM)-specific epidermal growth factor receptor variant III (EGFRvIII; CARvIII) have successfully treated tumors homogeneously expressing EGFRvIII when combined with lymphodepletion, however this is not recapitulated clinically. We generated an “armored” CARvIII which constitutively secretes IL-12, a stimulatory cytokine that enhances T cell persistence and function, that is capable of treating orthotopic heterogeneous GBM in immune competent mice.
METHODS
C57Bl/6 mice were intracranially (IC) implanted with 5 x 105 of either homogenous (CT2AvIII) or heterogeneous (1:1 CT2AvIII and CT2A parental) tumor cells. Mice were treated with 2 x 106 CARvIII or IL-12 CARvIII seven days post tumor implant and monitored for survival. TCRα -/-, CD8-/- and C57Bl/6 mice were IC implanted with homogeneous or heterogeneous tumors and treated 7 days post implant with intracranial IL-12 CARvIII therapy to assess the role of endogenous T cells. T cells within the tumor microenvironment were characterized by flow cytometry days 8, 14, and 17 post tumor implantation.
RESULTS
IL-12 CARvIII cells were successfully generated, secreted IL-12, and were cytotoxic against EGFRvIII-expressing tumor cells in vitro. IL-12 CARvIII therapy was curative in homogenous CT2AvIII tumors (p< 0.0001) and conferred a long-term survival in 50% of mice with heterogeneous CT2AvIII:CT2A parental tumors in vivo (p< 0.0001). Furthermore, IL-12 CARvIII therapy successfully eradicated the homogeneous CT2AvIII tumors in TCRα -/- and CD8-/- mice but failed to produce any efficacy against the heterogeneous CT2AvIII:CT2A parental tumors (p=0.0002). Endogenous T cells in IL-12 CARvIII treated mice were found to be more migratory, and interestingly more exhausted than in CARvIII treated mice.
CONCLUSIONS
Our findings show that IL-12 CARvIII can effectively eradicate IC homogenous tumors without lymphodepletion. Surprisingly, IL12 CARvIII therapy also treated IC heterogeneous glioma. Heterogeneous tumor clearance required an endogenous CD8 T cell response.
Collapse
Affiliation(s)
| | - Sarah Cook
- Brain Tumor Immunotherapy Program, Duke University , Durham, NC , USA
| | | | - Kelly Hotchkiss
- Brain Tumor Immunotherapy Program, Duke University , Durham , USA
| | | | | | - John Sampson
- The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center , Durham, NC , USA
| |
Collapse
|
4
|
Shen S, Reedy J, Suryadevara C, Hotchkiss K, Snyder D, Sanchez-Perez L, Sampson J. EXTH-18. IL-12 ARMORED CAR T CELL THERAPY FOR HETEROGENEOUS GLIOBLASTOMA. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
INTRODUCTION
Glioblastoma (GBM) is a lethal primary malignant brain tumor with a median survival of < 20 months. Our next generation immunotherapy utilizes chimeric antigen receptor (CAR) T cells targeted to GBM-specific overexpression of epidermal growth factor receptor variant III (EGFRvIII), “armored” with IL-12, a stimulatory cytokine that enhances T cell persistence and function, to treat orthotopic heterogeneous GBM.
METHODS
C57Bl/6 mice were intracranially implanted with 5 x 105 of either CT2AvIII tumor cells or a 1:1 mixture of CT2AvIII and CT2A parental tumor cells. Seven days post-implant, mice were treated with 2 x 106 IL-12 CARvIII and monitored for survival. For endogenous T cell activity assessment, TCRα -/- mice were intracranially implanted with either CT2AvIII cells or a 1:1 mixture of CT2AvIII:CT2A parental cells and treated 7 days post implant with intracranial IL-12 CARvIII therapy.
RESULTS
IL-12 CARvIII therapy was curative in the treatment of CT2AvIII homogeneous tumors and confers a long-term survival in 50% of CT2AvIII:CT2A mice. Furthermore, IL-12 CARvIII therapy successfully eradicated the homogeneous CT2AvIII tumors in TCRα-/- mice but failed to produce any efficacy against the heterogeneous CT2AvIII:CT2A parental tumors, suggesting that endogenous T cells are required for IL-12 CARvIII therapeutic success against heterogeneous tumors.
CONCLUSIONS
Our findings suggest that IL-12 CARvIII may be an effective treatment against heterogeneous glioma. Furthermore, this data provides insight on treatment against the immunosuppressive tumor microenvironment and applications against other solid tumors. In anticipation of translating this therapy into a phase I clinical trial, we are also investigating adjuvant therapies such irradiation to improve antitumor efficacy of IL-12 CARvIII against heterogeneous glioma.
Collapse
|
5
|
Swartz A, Congdon K, Nair S, Li QJ, Herndon J, Suryadevara C, Riccione K, Reedy J, Cook S, Archer G, Norberg P, Sanchez-Perez L, Sampson J. TMOD-14. CONJOINED CLASS I AND II EPITOPES ENHANCE NEOANTIGEN-TARGETED ACTIVE IMMUNOTHERAPY. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab196.875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
INTRODUCTION
Cancer vaccines involve the administration of tumor-associated antigens into the host to generate anti-tumor T cell responses. Glioblastoma (GBM) is a disease with poor prognosis. GBM has a limited number of immunotherapeutic targets due to low mutational load, and is also highly heterogeneous; targeting a single antigen leads to antigen escape and tumor growth.
METHODS
VMDK mice were subcutaneously implanted with 750,000 SMA560 cells and on days 1 and 8 post implantation, mice were treated with 15 nmol of the universal helper epitope, P30, conjoined to the MHCI-restricted neoepitopes Odc1MHCI-P30 or Topbp1MHCI-P30. Human CD27 (hCD27) transgenic mice were intracranially implanted with CT2A-Odc1, followed by anti-CD27 and 15 nmol of Odc1MHCI-P30. B16.OVA or B16.F10 tumor cells were intracranially implanted in hCD27 mice and received SIINFEKL-P30 or Trp2-P30 conjoined peptides. Tumor growth, survival, or IFNγ secretion of splenic or tumor-infiltrating cells was assessed.
RESULTS
Unlike Odc1MHCI mixed with P30, conjoined Odc1MHCI-P30 had equivalent immunogenicity and anti-tumor efficacy to that observed with native long Odc1 peptide. Native long peptide of Topbp1 did not elicit an antitumor response, yet Topbp1MHCI-P30 caused an increase in numbers of IFNγ-secreting splenocytes and a decrease in tumor growth and similar to that seen with Odc1MHCI-P30 . Anti-CD27 treatment significantly increased numbers of IFNγ secreting splenocytes in Odc1MHCI-P30 vaccinated hCD27 mice, and the use of anti-CD27 with Odc1MHCI-P30 achieved long-term survival in 90% of tumor bearing hCD27 mice. Anti-CD27 synergized with SIINFEKL-P30 and Trp2-P30 to significantly improve survival after administration of these peptides.
CONCLUSIONS
Our work shows that poorly immunogenic neoantigens can be conjoined to P30 and used to generate an anti-tumor response in mouse models of GBM, and anti-tumor responses of conjoined peptides can be enhanced with anti-CD27 treatment. Together, these data demonstrate the efficacy of neoantigen vaccines for the treatment of heterogeneous GBM.
Collapse
|